Patents Assigned to Institute Pasteur
  • Repertoire determination of a lymphocyte b population
    Publication number: 20070160994
    Abstract: The present invention provides a process for determining the quantitative and qualitative profile of the repertoire of a given type of an immunoglobulin (Ig) heavy chain expressed by a lymphocyte B population present in a tissue sample, and kits and uses thereof. It also provides a set of VII forward primers associated with a CII reverse primer, which are respectively capable of specifically hybridizing in stringent conditions with the nucleic acids encoding the variable segments of Ig heavy chains and with the constant segment of a given type of Ig heavy chain, such as preferably IgM, IgG, IgE or IgA heavy chain. Methods for the in vitrodiagnosis of a condition associated with an abnormal expression of the repertoire of a given type of Ig heavy chain, and for the in vitro follow-up of a treatment of such a condition, are also comprised herein.
    Type: Application
    Filed: December 15, 2004
    Publication date: July 12, 2007
    Applicants: INSTITUT PASTEUR, Institut National De La Sante Et De La Recherche M
    Inventors: Annick Lim, Brigitte Marie-Christine Lemercier, Philippe Kourilsky, Francois Huetz
  • Chimeric lyssavirus nucleic acids and polypeptides
    Patent number: 7238672
    Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 3, 2007
    Assignee: Institut Pasteur
    Inventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul
  • Method for detecting Nipah virus and method for providing immunoprotection against Henipa viruses
    Publication number: 20070150972
    Abstract: The present invention provides an animal model for monitoring Nipah virus infection, a method for the quantitative detection and rapid characterization of Nipah virus RNA in a sample, a composition which can be used to provide immunoprotection in an individual as well as monoclonal antibodies which neutralize Nipah and Hendra virus and can be used for prophylaxis, treatment, and/or prevention.
    Type: Application
    Filed: September 8, 2006
    Publication date: June 28, 2007
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Claude George Courbot, Fabian Wild, Vincent Deubel, Robin Buckland, Hugues Contamin, Thong Wong Kum, Philippe Loth
  • Chimeric lyssavirus nucleic acids and polypeptides
    Patent number: 7235245
    Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: June 26, 2007
    Assignee: Institut Pasteur
    Inventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul
  • DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)
    Patent number: 7232654
    Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: June 19, 2007
    Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jean-Claude Chermann, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
  • Enzymatic synthesis of deoxyribonucleosides
    Patent number: 7229797
    Abstract: The present invention relates to a method for the in vitro enzymatic synthesis of deoxyribonucleosides and enzymes suitable for this method.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: June 12, 2007
    Assignee: Institut Pasteur
    Inventors: Wilhelm Tischer, Hans-Georg Ihlenfeldt, Octavian Barzu, Hiroshi Sakamoto, Elisabeth Pistotnik, Philippe Marlière, Sylvie Pochet
  • Pknb kinase and pstp phosphatase and methods of identifying inhibitory substances
    Publication number: 20070128678
    Abstract: The present invention relates to a pknB kinase and a pstP phosphatase as well as their use for identifying antibacterial substances.
    Type: Application
    Filed: July 19, 2004
    Publication date: June 7, 2007
    Applicant: INSTITUT PASTEUR
    Inventors: Pedro Alzari, Brigitte Boitel, Andrea Villarino, Pablo Fernandez, Stewart Cole
  • Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)
    Patent number: 7217508
    Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.
    Type: Grant
    Filed: February 22, 1988
    Date of Patent: May 15, 2007
    Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human Services
    Inventors: Simon Wain-Hobson, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
  • Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
    Patent number: 7217534
    Abstract: A method of screening cellular polypeptides for pro-apoptotic or anti-apoptotic activity in a cell of a particular cell-type by: (a) culturing cells of the particular cell-type under non apoptotic conditions and culturing cells of the particular cell-type under apoptotic conditions, and (b) determining subcellular localization of the cellular polypeptides in the cultured cells, wherein a localization of a cellular polypeptide in lipid rafts in cultured cells under non apoptotic conditions and a segregation of the cellular polypeptide from lipid rafts in cultured cells under apoptotic conditions is indicative that the cellular polypeptide has a pro-apoptotic or an anti-apoptotic activity in the particular cell-type.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: May 15, 2007
    Assignees: Institut Pasteur, Consejo Superior de Investigaciones Cientificas, Centre National de la Recherche Scientifque
    Inventors: Alphonse Garcia, Xavier Cayla, Angelita Rebollo, Veronica Ayllon, Aarne Fleischer
  • Nucleic acids and new polypeptides associated with and/or overlapping with hepatitis C virus core gene products
    Patent number: 7217801
    Abstract: DNA encoding core+1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: May 15, 2007
    Assignees: Institute Pasteur, Hellenic Pasteur Institute
    Inventors: Penelope Mavromara, Agoritsa Varaklioto, Urania Georgopoulou
  • Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
    Patent number: 7214536
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: May 8, 2007
    Assignees: Institut Pasteur, University Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Vectors derived from antibodies for transferring substances into cells
    Publication number: 20070098741
    Abstract: The present invention provides novel polypeptides which can effectively penetrate into cells thereby transporting a substance of interest into the cells.
    Type: Application
    Filed: July 10, 2006
    Publication date: May 3, 2007
    Applicants: INSTITUT PASTEUR, Universite Pierre et Marie Curie
    Inventors: Therese Ternynck, Alexandre Avrameas, Gerard Buttin, Stratis Avrameas, Marie-Francoise Saron, Bruno Blondel, Therese Couderc, Susan Michelson, Donato Zipeto
  • MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE, VACCINE COMPRISING THE SAME AND USE THEREOF
    Publication number: 20070098730
    Abstract: A carbohydrate peptide conjugate comprising a carrier comprising a dendrimeric poly-Lysine enabling multipic epitopes to be covalently attached thereto, at least one peptide comprising one T epitope or several identical or different T epitopes, at least one carbohydrate moiety, or a derivative thereof, containing B epitope, provided it is not a sialoside, or several identical or different epitopes. Use of this conjugate for inducing immune response.
    Type: Application
    Filed: January 3, 2007
    Publication date: May 3, 2007
    Applicant: INSTITUT PASTEUR
    Inventors: Sylvie Bay, Daniele Cantacuzene, Claude Leclerc, Richard Lo-Man
  • antigens inducing protective antibodies
    Patent number: 7211256
    Abstract: The present invention relates, in part, to a purified polyclonal or monoclonal antibody which recognizes an epitope of a protein of 48,000 dalton, where the protein recognizes is a surface protein of a merozoite of Plasmodium falciparum which has a peptide of SEQ ID NO:1 or a sequence wherein SEQ ID NO:1 has been modified by insertion, deletion or substitution and the sequence inhibits the binding of monoclonal antibody 245 to Plasmodium merozoites, as well as fragments of the antibody; the present invention relates to composition and kits containing the same, as well as methods of using the same.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: May 1, 2007
    Assignee: Institut Pasteur
    Inventors: Pierre Druilhe, Hasnaq Bouharoun-Tayoun, Claude Oeuvray
  • Use of adenylate cyclase or bacteria producing it as vaccines against
    Patent number: 7211263
    Abstract: The invention relates to a method of immunizing a mammal against infection by a first Bordetella species. The method comprises administering to the mammal a preparation comprising a portion of the amino acid sequence of mature adenylate cyclase of a second Bordetella species. The invention also relates to vaccine preparations comprising a portion of the amino acid sequence of mature adenylate cyclase from Bordetella species.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: May 1, 2007
    Assignee: Institut Pasteur
    Inventor: Nicole Guiso-Maclouf
  • Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA
    Patent number: 7205102
    Abstract: This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 17, 2007
    Assignees: Institut Pasteur, The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Luc Montagnier, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Jean-Claude Chermann, Francoise Barre-Sinoussi, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
  • Peptides binding the phosphatase 2A protein and polynucleotides encoding same
    Publication number: 20070065410
    Abstract: The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or one of its subunits. The invention also relates to polynucleotides encoding the novel peptides, vectors expressing same, as well as antibodies identifying same and probes identifying transcripts thereof.
    Type: Application
    Filed: April 18, 2005
    Publication date: March 22, 2007
    Applicant: INSTITUT PASTEUR
    Inventors: Alphonse Garcia, Frederic Dessauge, Xavier Cayla, Angelita Rebollo
  • Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
    Patent number: 7189403
    Abstract: The present invention relates to nine residue peptides (ApoptoM) from flavivirus M ectodomain able to modulate specifically the apoptotic activity of diverse flavivirus, to pharmaceutical composition comprising the same and their use for the treatment and/or the prevention of flavivirus-linked infections and cancers.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: March 13, 2007
    Assignee: Institut Pasteur
    Inventors: Philippe Despres, Adeline Catteau
  • Therapeutic uses of SMR1 peptides
    Publication number: 20070054861
    Abstract: The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human.
    Type: Application
    Filed: November 8, 2006
    Publication date: March 8, 2007
    Applicants: INSTITUT PASTEUR, Centre National De La Racherche Scient
    Inventors: Catherine Rougeot, Francois Rougeon
  • Peptides of IL-2
    Publication number: 20070048302
    Abstract: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.
    Type: Application
    Filed: July 28, 2006
    Publication date: March 1, 2007
    Applicant: INSTITUT PASTEUR
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Golberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie